These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
351 related items for PubMed ID: 16200082
1. Regulation of MHC class II gene expression by the class II transactivator. Reith W, LeibundGut-Landmann S, Waldburger JM. Nat Rev Immunol; 2005 Oct; 5(10):793-806. PubMed ID: 16200082 [Abstract] [Full Text] [Related]
2. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. EMBO J; 1997 May 15; 16(10):2851-60. PubMed ID: 9184229 [Abstract] [Full Text] [Related]
3. Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes. LeibundGut-Landmann S, Waldburger JM, Krawczyk M, Otten LA, Suter T, Fontana A, Acha-Orbea H, Reith W. Eur J Immunol; 2004 Jun 15; 34(6):1513-25. PubMed ID: 15162420 [Abstract] [Full Text] [Related]
4. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Holling TM, Schooten E, van Den Elsen PJ. Hum Immunol; 2004 Apr 15; 65(4):282-90. PubMed ID: 15120183 [Abstract] [Full Text] [Related]
5. Differential nerve injury-induced expression of MHC class II in the mouse correlates to genetic variability in the type I promoter of C2ta. Harnesk K, Swanberg M, Diez M, Olsson T, Piehl F, Lidman O. J Neuroimmunol; 2009 Jul 25; 212(1-2):44-52. PubMed ID: 19481818 [Abstract] [Full Text] [Related]
6. Revisiting the specificity of the MHC class II transactivator CIITA in vivo. Otten LA, Leibundgut-Landmann S, Huarte J, Kos-Braun IC, Lavanchy C, Barras E, Borisch B, Steimle V, Acha-Orbea H, Reith W. Eur J Immunol; 2006 Jun 25; 36(6):1548-58. PubMed ID: 16703565 [Abstract] [Full Text] [Related]
7. Regulation of MHC class II expression, a unique regulatory system identified by the study of a primary immunodeficiency disease. Krawczyk M, Reith W. Tissue Antigens; 2006 Mar 25; 67(3):183-97. PubMed ID: 16573555 [Abstract] [Full Text] [Related]
8. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S. Cancer Res; 2006 Jan 15; 66(2):1147-54. PubMed ID: 16424052 [Abstract] [Full Text] [Related]
9. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator. Radosevich M, Jager M, Ono SJ. Exp Mol Pathol; 2007 Feb 15; 82(1):68-76. PubMed ID: 16650406 [Abstract] [Full Text] [Related]
10. Epigenetic silencing of MHC2TA transcription in cancer. Holling TM, van Eggermond MC, Jager MJ, van den Elsen PJ. Biochem Pharmacol; 2006 Nov 30; 72(11):1570-6. PubMed ID: 16879803 [Abstract] [Full Text] [Related]
12. MHC class II expression is differentially regulated in plasmacytoid and conventional dendritic cells. LeibundGut-Landmann S, Waldburger JM, Reis e Sousa C, Acha-Orbea H, Reith W. Nat Immunol; 2004 Sep 30; 5(9):899-908. PubMed ID: 15322541 [Abstract] [Full Text] [Related]
13. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation. Li D, Qian L, Chen C, Shi M, Yu M, Hu M, Song L, Shen B, Guo N. J Immunol; 2009 Feb 15; 182(4):1799-809. PubMed ID: 19201831 [Abstract] [Full Text] [Related]
14. Epigenetic control of MHC-II: interplay between CIITA and histone-modifying enzymes. Zika E, Ting JP. Curr Opin Immunol; 2005 Feb 15; 17(1):58-64. PubMed ID: 15653312 [Abstract] [Full Text] [Related]
15. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells. Meissner M, Whiteside TL, Kaufmann R, Seliger B. Arch Dermatol Res; 2009 Feb 15; 301(2):189-93. PubMed ID: 19104823 [Abstract] [Full Text] [Related]
16. Control of MHC class II gene expression in autoimmune, infectious, and neoplastic diseases. Guardiola J, Maffei A. Crit Rev Immunol; 1993 Feb 15; 13(3-4):247-68. PubMed ID: 8110378 [Abstract] [Full Text] [Related]
17. Constitutive and IFNgamma-induced activation of MHC2TA promoter type III in human melanoma cell lines is governed by separate regulatory elements within the PIII upstream regulatory region. van der Stoep N, Quinten E, Alblas G, Plancke A, van Eggermond MC, Holling TM, van den Elsen PJ. Mol Immunol; 2007 Mar 15; 44(8):2036-46. PubMed ID: 17067677 [Abstract] [Full Text] [Related]
18. [Construction of mutants of MHC class II molecule transactivator gene capable of suppressing HLA-DR/DQ expression and exploration on their mechanism]. Ou QS, Lin L, Huang LD, Lu PH, Zhou GY. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Sep 15; 19(5):417-20. PubMed ID: 15169643 [Abstract] [Full Text] [Related]
19. N-terminal destruction signals lead to rapid degradation of the major histocompatibility complex class II transactivator CIITA. Schnappauf F, Hake SB, Camacho Carvajal MM, Bontron S, Lisowska-Grospierre B, Steimle V. Eur J Immunol; 2003 Aug 15; 33(8):2337-47. PubMed ID: 12884309 [Abstract] [Full Text] [Related]
20. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins. Broxmeyer HE, Cooper S, Hangoc G, Chang CH. Exp Hematol; 2006 Aug 15; 34(8):1078-84. PubMed ID: 16863914 [Abstract] [Full Text] [Related] Page: [Next] [New Search]